KROS241220P65000
- 0.00
- 0.000.00%
Keros Therapeutics Newsroom
Wedbush Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $84
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $105
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $84 to $105
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $80 to $105
Keros Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Wedbush Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $84
Jefferies Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $107
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Cantor Fitzgerald Initiates Keros Therapeutics(KROS.US) With Buy Rating
Keros Therapeutics Analyst Ratings
Keros Therapeutics Initiated With an Outperform at Scotiabank
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), Travere Therapeutics (TVTX) and Keros Therapeutics (KROS)
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Keros Therapeutics (KROS)
Guggenheim Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $96
Keros Therapeutics Is Maintained at Buy by B of A Securities
Keros Therapeutics Analyst Ratings
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $76
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)